Search
Press release
North America
Parsippany, May 19, 2020

Evonik and Glenn Corporation expand partnership for cosmetic product protection line in the United States

  • Glenn Corporation appointed exclusive distributor in U.S.
  • Wide range of natural and sustainable alternatives for product protection by Evonik’s Dr. Straetmans brand available to U.S. customers
  • Further expansion of existing long-term relationship with Glenn Corporation

Evonik and Glenn Corporation, a division of Azelis Americas, announced the signing of an exclusive agreement which enables Glenn to distribute the product protection line by Evonik’s Dr. Straetmans brand in the United States, effective May 1, 2020. Evonik Dr. Straetmans offers a wide range of natural and sustainable alternatives for stabilizing and protecting cosmetic products.

This strategic expansion of Evonik’s existing relationship with Glenn builds upon the strengths of over 30 years of history as trusted partners in servicing the beauty care market, achieving consistent growth through mutual recognition for technical competence and marketing excellence.

“With our strengthened partnership with Glenn Corporation, we are further expanding our sales channels and broadening the reach and support of our solutions to customers in the United States. We are happy to offer a more complete set of solutions for formulation development, enabling the brands we support to adapt and innovate more quickly to changing consumer needs,” said Ron Birnbaum, head of Evonik’s Care Solutions Business Line in North America.

The Evonik Dr. Straetmans product range includes multifunctional antimicrobials and preservative blends, antioxidants and chelating agents. The portfolio also comprises natural active ingredients with selected activity against specific microorganisms that cause different skin disorders such as dandruff, body odor or oily, blemish-prone skin.

In addition to functionally complementing existing Evonik products offered by Glenn, the Evonik Dr. Straetmans portfolio also presents Glenn customers with enhanced capabilities to address needs and trends stemming from natural and sustainable cosmetics.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,100 employees, and generated sales of around €4.58 billion in 2019.

About Glenn Corporation

Glenn, an Azelis company, provides comprehensive service through the delivery of specialty chemical solutions for the formulation of Personal Care and Home Care & Industrial Cleaning products. Glenn’s super-regional footprint accompanied by their technical competence and optimized marketing platform exemplify their value-added standards to both our supplier partners and customers.

Azelis is a leading distributor of specialty chemicals and food ingredients present in over 40 countries across the globe with around 1,800 employees. Azelis’ knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.